MA33923B1 - Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a - Google Patents

Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a

Info

Publication number
MA33923B1
MA33923B1 MA35064A MA35064A MA33923B1 MA 33923 B1 MA33923 B1 MA 33923B1 MA 35064 A MA35064 A MA 35064A MA 35064 A MA35064 A MA 35064A MA 33923 B1 MA33923 B1 MA 33923B1
Authority
MA
Morocco
Prior art keywords
present
formula
relates
subject
inhibitors
Prior art date
Application number
MA35064A
Other languages
Arabic (ar)
English (en)
Inventor
Ask Püschl
Jacob Nielsen
Jan Kehler
John Paul Kilburn
Mauro Marigo
Morten Langgård
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MA33923B1 publication Critical patent/MA33923B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention a pour objet des composés (Formule 1) qui sont des inhibiteurs de l'enzyme PDE10A. La présente invention concerne une composition pharmaceutique comprenant une quantité thérapeutiquement efficace d'un composé selon l'invention et un véhicule pharmaceutiquement acceptable. La présente invention concerne également des procédés pour la préparation des composés de formule (I). La présente invention concerne en outre une méthode de traitement d'un sujet souffrant d'un trouble neurodégénératif comprenant l'administration au sujet d'une quantité thérapeutiquement efficace d'un composé de formule (I). La présente invention concerne également une méthode de traitement d'un sujet souffrant d'une pharmacodépendance comprenant l'administration au sujet d'une quantité thérapeutiquement efficace d'un composé de formule (I). La présente invention concerne en outre une méthode de traitement d'un sujet souffrant d'un trouble psychiatrique comprenant l'administration au sujet d'une quantité thérapeutiquement efficace d'un composé de formule (I).
MA35064A 2009-12-17 2010-12-15 Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a MA33923B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28732109P 2009-12-17 2009-12-17
DKPA200901340 2009-12-17
PCT/DK2010/050344 WO2011072697A1 (fr) 2009-12-17 2010-12-15 Dérivés hétéroaromatiques d'aryltriazole en tant qu'inhibiteurs de l'enzyme pde10a

Publications (1)

Publication Number Publication Date
MA33923B1 true MA33923B1 (fr) 2013-01-02

Family

ID=44246811

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35064A MA33923B1 (fr) 2009-12-17 2010-12-15 Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a

Country Status (36)

Country Link
US (2) US8501795B2 (fr)
EP (1) EP2513106B1 (fr)
JP (1) JP6035149B2 (fr)
KR (1) KR101779629B1 (fr)
CN (1) CN102753550B (fr)
AR (1) AR079496A1 (fr)
AU (1) AU2010333438B2 (fr)
BR (1) BR112012014486A2 (fr)
CA (1) CA2783728C (fr)
CO (1) CO6602117A2 (fr)
CR (1) CR20120318A (fr)
CY (1) CY1116361T1 (fr)
DK (1) DK2513106T3 (fr)
DO (1) DOP2012000169A (fr)
EA (1) EA021606B1 (fr)
ES (1) ES2442179T3 (fr)
GE (1) GEP20146201B (fr)
GT (1) GT201200193A (fr)
HR (1) HRP20131210T1 (fr)
IL (1) IL220328A (fr)
MA (1) MA33923B1 (fr)
MX (1) MX2012006715A (fr)
MY (1) MY156520A (fr)
NZ (1) NZ600365A (fr)
PH (1) PH12012501202A1 (fr)
PL (1) PL2513106T3 (fr)
PT (1) PT2513106E (fr)
RS (1) RS53101B (fr)
SG (1) SG181672A1 (fr)
SI (1) SI2513106T1 (fr)
SM (1) SMT201400009B (fr)
TN (1) TN2012000278A1 (fr)
TW (1) TWI487705B (fr)
UA (1) UA107950C2 (fr)
WO (1) WO2011072697A1 (fr)
ZA (1) ZA201204420B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI487705B (zh) * 2009-12-17 2015-06-11 Lundbeck & Co As H 作為pde10a酵素抑制劑之雜芳香族芳基三唑衍生物
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為pde10a酵素抑制劑的2-芳基咪唑衍生物
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為pde10a酵素抑制劑之雜芳香族苯基咪唑衍生物
WO2012096929A2 (fr) 2011-01-11 2012-07-19 Sunovion Pharmaceuticals Inc. Composés hétéroaryles et leurs procédés d'utilisation
KR20140009372A (ko) 2011-02-18 2014-01-22 알러간, 인코포레이티드 포스포다이에스테라제 10(pde10a)의 억제제로서의 치환된 6,7-다이알콕시-3-아이소퀴놀리놀 유도체
PE20141553A1 (es) * 2011-09-19 2014-10-30 Hoffmann La Roche Compuestos de triazolopiridina como inhibidores de la ped10a
WO2013127817A1 (fr) 2012-02-27 2013-09-06 H. Lundbeck A/S Dérivés d'imidazole comme inhibiteurs de l'enzyme pde10a
EA201492069A1 (ru) 2012-05-30 2015-03-31 Ф.Хоффманн-Ля Рош Аг Соединения триазола в качестве ингибиторов фосфодиэстеразы 10 (pde10)
NZ702239A (en) * 2012-06-19 2017-01-27 Sunovion Pharmaceuticals Inc Heteroaryl compounds and methods of use thereof
WO2014071044A1 (fr) 2012-11-01 2014-05-08 Allergan, Inc. Dérivés de 6,7-dialcoxy-3-isoquinoline substitués à titre d'inhibiteurs de phosphodiestérase 10 (pde10a)
WO2014078216A1 (fr) * 2012-11-15 2014-05-22 Merck Sharp & Dohme Corp. Cyclobutyl benzimidazoles en tant qu'inhibiteurs de pde10
EP3074387B1 (fr) * 2013-11-28 2017-11-08 F.Hoffmann-La Roche Ag Dérivés d'imidazole
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
CN114671874B (zh) * 2021-08-30 2024-02-02 济南爱思医药科技有限公司 一种具有抗肿瘤活性的茶碱乙酸衍生物及其制备方法与应用
US20250034112A1 (en) * 2021-10-13 2025-01-30 Yale University Improved selective jak2 inhibitors and methods of use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1462521A (en) 1974-02-11 1977-01-26 Wyeth John & Brother Ltd Triazole derivatives
GB8307865D0 (en) 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
US5571775A (en) 1994-07-11 1996-11-05 Dowelanco N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides
US6699853B2 (en) 1997-06-16 2004-03-02 Hoechst Schering Agrevo Gmbh 4-haloalkyl-3-heterocyclylpyridines, 4-haloalkyl-5-heterocyclyl-pyrimidines and 4-trifluoromethyl-3-oxadiazolylpyridines, processes for their preparation, compositions comprising them, and their use as pesticides
SE9802937D0 (sv) 1998-09-01 1998-09-01 Astra Pharma Prod Novel compounds
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
IL149106A0 (en) 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
FR2824065A1 (fr) 2001-04-26 2002-10-31 Neuro3D Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations
US20060128695A1 (en) 2002-10-30 2006-06-15 Neuro3D Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses
TW200510407A (en) 2003-06-30 2005-03-16 Altana Pharma Ag Novel pyrrolodihydroisoquinolines as PDE 10 inhibitors
ATE438398T1 (de) 2003-06-30 2009-08-15 Nycomed Gmbh Pyrrolo-dihydroisochinolin-derivate als pde10- inhibitoren
WO2005012485A2 (fr) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Procedes pour traiter le diabete, et les troubles associes, au moyen d'inhibiteurs des pde10a
JP2007523152A (ja) 2004-02-18 2007-08-16 ファイザー・プロダクツ・インク キナゾリンおよびイソキノリンのテトラヒドロイソキノリニル誘導体
FR2870539B1 (fr) 2004-05-19 2006-08-04 Greenpharma Sa Sa Nouvelles methodes et medicaments
EP1755611A1 (fr) 2004-06-07 2007-02-28 Pfizer Products Inc. Inhibition de la phosphodiesterase 10 dans le traitement des etats pathologiques associes a l'obesite et au syndrome metabolique
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
JP2008512375A (ja) 2004-09-03 2008-04-24 メモリ ファーマセチカル コーポレーション 精神医学的又は神経学的症候群の治療用のホスホジエステラーゼ10阻害剤としての4−置換4,6−ジアルコキシ−シンノリン誘導体
NL2000397C2 (nl) * 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
US20080090834A1 (en) * 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
HRP20120835T1 (hr) * 2006-07-10 2012-11-30 H. Lundbeck A/S (3-aril-piperazin-1-il) derivati 6,7-dialkoksikinazolina, 6,7-dialkoksiftalazina i 6,7-dialkoksiizokinolina
WO2009011880A2 (fr) 2007-07-17 2009-01-22 Amgen Inc. Modulateurs hétérocycliques de pkb
GB0800411D0 (en) 2008-01-10 2008-02-20 Glaxo Group Ltd Novel compounds
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為pde10a酵素抑制劑的2-芳基咪唑衍生物
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為pde10a酵素抑制劑之雜芳香族芳基三唑衍生物
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為pde10a酵素抑制劑之雜芳香族苯基咪唑衍生物
JP5911476B2 (ja) * 2010-05-26 2016-04-27 スノビオン プハルマセウトイカルス インコーポレイテッド ヘテロアリール化合物及びその使用方法

Also Published As

Publication number Publication date
PT2513106E (pt) 2014-01-20
CY1116361T1 (el) 2017-02-08
CN102753550A (zh) 2012-10-24
EA201290517A1 (ru) 2012-12-28
NZ600365A (en) 2013-10-25
IL220328A (en) 2014-12-31
TN2012000278A1 (en) 2013-12-12
BR112012014486A2 (pt) 2017-04-04
SI2513106T1 (sl) 2014-01-31
TWI487705B (zh) 2015-06-11
US20120309764A1 (en) 2012-12-06
US8501795B2 (en) 2013-08-06
EP2513106B1 (fr) 2013-11-06
CO6602117A2 (es) 2013-01-18
TW201130834A (en) 2011-09-16
CN102753550B (zh) 2015-03-25
AU2010333438B2 (en) 2016-03-10
US20130281459A1 (en) 2013-10-24
EP2513106A1 (fr) 2012-10-24
EA021606B1 (ru) 2015-07-30
AU2010333438A1 (en) 2012-06-21
JP6035149B2 (ja) 2016-11-30
IL220328A0 (en) 2012-08-30
HRP20131210T1 (hr) 2014-01-17
US8785653B2 (en) 2014-07-22
MX2012006715A (es) 2012-07-03
GEP20146201B (en) 2014-11-25
PL2513106T3 (pl) 2014-09-30
CA2783728A1 (fr) 2011-06-23
CA2783728C (fr) 2018-06-12
UA107950C2 (en) 2015-03-10
KR20120113215A (ko) 2012-10-12
SG181672A1 (en) 2012-07-30
SMT201400009B (it) 2014-03-07
GT201200193A (es) 2013-09-26
JP2013514286A (ja) 2013-04-25
ZA201204420B (en) 2013-09-25
DK2513106T3 (da) 2014-01-13
HK1177745A1 (en) 2013-08-30
KR101779629B1 (ko) 2017-09-18
MY156520A (en) 2016-02-26
AR079496A1 (es) 2012-02-01
CR20120318A (es) 2012-08-16
ES2442179T3 (es) 2014-02-10
WO2011072697A1 (fr) 2011-06-23
RS53101B (sr) 2014-06-30
DOP2012000169A (es) 2012-12-15
PH12012501202A1 (en) 2021-06-23

Similar Documents

Publication Publication Date Title
MA33923B1 (fr) Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a
MA37958A1 (fr) Pde9i ayant un squelette imidazo pyrazinone
MY152949A (en) Novel phenylimidazole derivatives as pde10a enzyme inhibitors
UA102693C2 (ru) Производные фенилимидазола как ингибиторы фермента pde10a
MA31447B1 (fr) Nouveaux dérivés d'acide dicarboxylique utilisés comme agonistes du récepteur s1p1
TN2012000287A1 (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
UA112065C2 (uk) Похідні імідазолу як інгібітори ферменту pde10a
MA33922B1 (fr) Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a
MA32108B1 (fr) Derives d'indazole
MA35404B1 (fr) Composés pour le traitement de la toxicomanie
MA35874B1 (fr) Dérivés d'amide cycliques à utiliser en tant qu'inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase et utilisations de ceux-ci
MA35875B1 (fr) Dérivés d'aza-adamantane et leurs utilisations
MA60099B1 (fr) Dérivés de tétrazole utiles en tant qu'inhibiteurs de trpa1
MA60100B1 (fr) Dérivés de tétrazole utiles en tant qu'inhibiteurs de trpa1
MA34736B1 (fr) Dérivé d'imidazole en tant qu'inhibiteurs de l'enzyme pde10a
MA54940B1 (fr) Dérivés d'acides aminés pour le traitement de maladies inflammatoires
MA35882B1 (fr) Inhibiteurs de pde9 comprenant un squelette imidazotriazinone
TN2010000111A1 (fr) Nouveaux sels d'addition d'inhibiteurs d'enzyme de conversion de l'angiotensine a des acides donneurs de no, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA35860B1 (fr) Dérivés de quinoléine en tant qu'inhibiteurs d'enzyme pde10a
MA31356B1 (fr) Utilisation d'inhibiteurs de la hdac pour le traitement des cancers gastro-intestinaux
TN2010000387A1 (fr) Derives d'indazole
MA34196B1 (fr) Dérivés d'imidazole condensés comme antagonistes de trpv3
MA34198B1 (fr) Dérivés de chroménone convenant comme antagonistes trpv3
MA34195B1 (fr) Derives du chromane comme modulateurs de trpv3